US Bancorp’s Atea Pharmaceuticals AVIR Stock Holding History

US Bancorp’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64	Closed	-$344	–	4171
2026 Q1	$344	Buy	+64	New	+$294	﹤0.01%	4039
2025 Q3	–	Sell	-5,470	Closed	-$19.7K	–	4024
2025 Q2	$19.7K	Sell	5,470 -540	-9%	-$1.61K	﹤0.01%	3172
2025 Q1	$18K	Buy	+6,010	New	+$18.8K	﹤0.01%	3216
2024 Q2	–	Sell	-2,900	Closed	-$11.7K	–	3979
2024 Q1	$11.7K	Buy	+2,900	New	+$11.3K	﹤0.01%	3284
2023 Q3	–	Sell	-1,015	Closed	-$3.8K	–	3988
2023 Q2	$3.8K	Buy	+1,015	New	+$3.8K	﹤0.01%	3553
2023 Q1	–	Sell	-264	Closed	-$1.27K	–	4086
2022 Q4	$1.27K	Sell	264 -100	-27%	-$506	﹤0.01%	3882
2022 Q3	$2K	Buy	+364	New	+$2.79K	﹤0.01%	3798
2022 Q2	–	Sell	-207	Closed	-$1K	–	4074
2022 Q1	$1K	Sell	207 -42	-17%	-$285	﹤0.01%	3911
2021 Q4	$2K	Buy	249 +202	+430%	+$3.15K	﹤0.01%	3863
2021 Q3	$2K	Buy	47 +32	+213%	+$888	﹤0.01%	3854
2021 Q2	$0	Buy	+15	New	+$451	﹤0.01%	3990

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

US Bancorp's AVIR Position: Q2 2026 in Review

US Bancorp sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 64 shares — an estimated $344 sold.

US Bancorp first reported a position in AVIR in Q2 2021 and held it in 11 quarters. The position peaked at $19.7K in Q2 2025. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

US Bancorp reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 64 Atea Pharmaceuticals shares in Q2 2026, an estimated $344.
US Bancorp first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 11 quarters.
US Bancorp's Atea Pharmaceuticals position peaked at $19.7K in Q2 2025.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.